
Who's online
There are currently 8 users and 255 guests online.
Online users
- Inga
- MUTOMBO MULANGU A...
- patrick sampao
- nicoM
- nick golding
- Kabogo
- Moon
- Sysadmin
News Flash
Recent blog posts
- Where the real battle is won
- Amazing statements by leading malariologists
- How was malaria of 100 years ago eradicated in Palestine/Israel? And without vaccine?
- Winston Hide's courageous move
- Event: Symposium Malaria, maternal and infant health
- Job: Senior Lecturer / Lecturer in Epidemiology
- Job: Inspiring scientists in infectious tropical diseases
- Can we maintain effectiveness of the tools?
- Advertising on MalariaWorld
- Malaria elimination country briefings published by the UCSF Global Health Group
Active forum topics
- The role of community education and involvement in malaria control
- Introduce yourself to MalariaWorld members
- Fighting drug resistance by switching to environmental management of mosquito habitats
- Need for additional group to supplement WHO in fight against malaria
- Sustainable additions to WHO and PMI strategy
New forum topics
- Fighting drug resistance by switching to environmental management of mosquito habitats
- Grand Challemges Canada round 2. Help fund a malaria related project!
- Open Access 2.0:How to achieve this
- Pouring gasoline on the insecticide resistance fire?
- Need for additional group to supplement WHO in fight against malaria
The combination of fosmidomycin and clindamycin (F/C) is effective in adults and older children for the treatment of malaria and could be an important alternative to existing artemisinin-based combinations (ACTs) if proven to work in younger children.
Plasmodium falciparum blood-stage antigens such as merozoite surface protein 1 (MSP-1), apical membrane antigen 1 (AMA-1), and the 175-kDa erythrocyte binding antigen (EBA-175) are considered important targets of naturally acquired immunity to malaria.
A malaria case was defined as a positive result for malaria by microscopy in a patient with fever or history of fever in the previous 24 hours.
The study suggests that the contribution of IRS to malaria and mosquito control is not entirely perceived by the beneficiaries, and that other as cost effective interventions such as insecticide-treated nets are favoured over IRS.
To become widely diffused, best practices suggest that end-users should be included in product development to ensure that preferred attributes or traits are considered.
These results demonstrate the potential of climate predictors particularly, humidity and maximum temperature in explaining malaria incidence risk for the studied period in Maputo province.
Both An. gambiae s.s. and An. funestus were controlled effectively with the DDT-based IRS programme in Zambezia, reducing disease transmission and burden.
The RTS,S/AS02D malaria vaccine administered to young infants has a good safety profile and remains efficacious over 14 months.
